Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
- 1 February 2026
- journal article
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (2) , 185-198
Abstract
Objective: This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile. Method: A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms. Result: Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives. Conclusion: Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.Keywords
This publication has 54 references indexed in Scilit:
- Liquid chromatography and liquid chromatography coupled with tandem mass spectrometry studies for the identification and characterization of degradation products of lobeglitazoneSeparation Science Plus, 2024
- Quantitative determination of lobeglitazone sulfate and glimepiride in combined tablet by robust high‐performance thin layer chromatographic methodSeparation Science Plus, 2024
- Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of LobeglitazoneClinical Pharmacology in Drug Development, 2022
- Thiazolidinediones: the Forgotten Diabetes MedicationsCurrent Diabetes Reports, 2019
- The current role of thiazolidinediones in diabetes managementArchives of Toxicology, 2016
- Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in RatsJournal of Pharmaceutical Sciences, 2015
- CKD‐501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeksJournal of Applied Toxicology, 2013
- Quantitative and Qualitative Analysis of CKD-501, Lobeglitazone, in Human Plasma and Urine Using LC–MS/MS and Its Application to a Pharmacokinetic StudyChromatographia, 2012
- Case series of liver failure associated with rosiglitazone and pioglitazonePharmacoepidemiology and Drug Safety, 2009
- The mode of action of thiazolidinedionesDiabetes/Metabolism Research and Reviews, 2002